You are here:

fluticasone furoate / umeclidinium / vilanterol (Trelegy Ellipta)

Advice

Following an abbreviated submission:

fluticasone furoate / umeclidinium / vilanterol (as trifenatate) (Trelegy® Ellipta®) is accepted for restricted use within NHS Scotland.

Indication under review: maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist.

SMC restriction: in patients with severe COPD (forced expiratory volume in one second [FEV1] <50% predicted normal).

Trelegy Ellipta costs less than inhalers containing fluticasone furoate / vilanterol (as trifenatate) 92 micrograms /22 micrograms and umeclidinium 55 micrograms administered separately. 

Drug Details

Drug Name: fluticasone furoate / umeclidinium / vilanterol (Trelegy Ellipta)
SMC Drug ID: 1303/18
Manufacturer: GlaxoSmithKline UK Ltd
Indication: Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist.
BNF Category:
Submission Type: Abbreviated Submission
Status: Restricted
Date Advice Published: 12 February 2018

Back